This article is more than 5 years old. Information may no longer be current.

VIDEO: MAJESTIC trial produces ‘encouraging results’ at 2 years

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — In this video exclusive, Stefan Müller-Hülsbeck, MD, discusses new 2-year data from the MAJESTIC trial of a drug-eluting vascular stent system for treatment of femoropopliteal artery lesions.

Müller-Hülsbeck, a principal investigator of the trial, and colleagues evaluated use of the Eluvia drug-eluting vascular stent system (Boston Scientific) for treatment of femoropopliteal artery lesions up to 110 mm in length. The system includes the Innova self-expanding nitinol stent platform and a fluoropolymer-paclitaxel coating.

Two-year data on 57 patients yielded a high rate of freedom from target lesion revascularization, a low rate of reintervention and a good safety profile, according to Müller-Hülsbeck, from Ev-Luth Diakonissenanstalt zu Flensburg, Germany.

The upcoming IMPERIAL trial comparing the safety and effectiveness of the Eluvia drug-eluting vascular stent system vs. the Zilver PTX drug-eluting peripheral stent (Cook Medical) will provide more information on outcomes in this patient population, he said.